Artificial intelligence and machine learning companies develop software, algorithms and computational platforms that analyse biological data, automate workflows and accelerate scientific discovery. These technologies are increasingly used across drug discovery, diagnostics, genomics and healthcare research.
This category includes companies working on:
Browse 243 UK AI and machine learning companies below.
Antibody therapeutics for inflammatory and autoimmune disease
MabGalaxy develops antibody therapeutics for inflammatory and autoimmune diseases, with scientific operations linked to Cambridge's Babraham Research Campus. Its discovery approach combines immune-system biology with artificial intelligence to support antibody design and selection. The company aims to shorten the…
API-first diagnostic infrastructure and biomarker services for healthcare companies
Hurdle is a London-based diagnostics-as-a-service company providing end-to-end diagnostic infrastructure to telehealth companies, consumer health brands, pharmaceutical companies, and clinical research organisations. Its platform integrates sample collection kit manufacturing, accredited laboratory networks,…
AI-guided synthetic lethality drug discovery for oncology
Evariste is a drug discovery company developing small-molecule inhibitors of synthetic lethal targets in cancer. Its computational platform combines machine learning, multimodal biological data and molecular modelling to identify therapeutic targets, design candidate compounds and prioritise laboratory testing. The…
AI-assisted imaging software for minimally invasive vascular surgery
Cydar Medical is a medical software company developing AI-assisted imaging tools for minimally invasive vascular surgery. Its cloud-based platform creates three-dimensional anatomical maps from CT scans and overlays them on live X-ray images to support procedural planning and intraoperative navigation. The software…
AI platform engineering molecular glue drugs for undruggable targets
Ternary Therapeutics is a preclinical-stage biotechnology company developing an AI-driven platform for the rational design of molecular glue therapeutics. Molecular glues are small molecules that induce proximity between two proteins, enabling targeted degradation or modulation of disease-driving targets that lack…
AI-enabled biologics discovery and therapeutic development
Divergence Labs develops new medicines by combining molecular engineering, machine learning and high-throughput biological experimentation. Its Cambridge research team integrates antibody and biologics discovery, cell engineering and automated screening to identify and optimise therapeutic candidates. Proprietary…
Genomics platform developing RNA therapies for chronic liver disease
Ochre Bio is a biotechnology company developing RNA therapeutics for chronic liver disease using a platform built on large-scale human liver datasets. The platform integrates gene perturbation atlases, single-cell genomics from perfused donor livers, and machine learning to identify and validate disease-modifying drug…
AI-assisted clinical development and real-world evidence analysis
Inovia Bio is a software and research-services company developing AI-assisted tools for clinical drug development and evidence planning. Its InovaSight platform integrates clinical trial records, scientific publications and regulatory information to support indication prioritisation, trial design and development…
Molecular and digital biomarkers for personalised cancer treatment
Oxford Cancer Biomarkers is a precision oncology diagnostics company developing molecular and digital pathology tests to support personalised cancer treatment. Its pharmacogenomic assays assess inherited variants associated with fluoropyrimidine chemotherapy toxicity, while its algorithm-driven pathology tools analyse…
Gut microbiome tests predicting biologic drug response in IBD
AlphaBiomics is a precision medicine company developing diagnostics that analyse the gut microbiome to guide treatment decisions. Its lead test uses a stool sample collected at home and machine learning analysis of microbial sequencing data to predict which patients with inflammatory bowel disease are likely to…
National innovation centre accelerating drug discovery
Medicines Discovery Catapult (MDC) is an independent, not-for-profit national innovation centre that supports UK medicines discovery organisations across the full drug discovery pipeline. MDC provides access to specialist laboratory technologies, computational and AI-driven tools, translational R&D expertise, and…
AI drug discovery platform targeting neurological diseases
CoSyne Therapeutics is a drug discovery company applying AI and computational methods to identify and develop therapeutics for neurological diseases. The company describes its approach as polymathic AI, integrating models across biology, chemistry, and genomics to generate and prioritise drug targets. CoSyne operates…
Global drug discovery and development partnership company
Evotec is a global drug discovery and development company with major UK operations at Milton Park, Abingdon, and Alderley Park, Cheshire. Its Abingdon campus houses over 800 staff spanning target validation, medicinal chemistry, structural biology, in silico design, process development, and biologics manufacturing…
Human ovarian cell models and multi-omics drug discovery
OvartiX is a Cambridge biotechnology company developing drug-discovery tools and therapeutic programmes for ovarian and reproductive health. Its platform combines human multi-omics datasets, machine learning and engineered two- and three-dimensional ovarian cell models to identify and validate disease targets. Founded…
Single-cell somatic mutation analysis for measuring biological ageing
AgeCurve is a geroscience company developing diagnostics that measure biological ageing at the level of individual cells. Its approach analyses the burden and lineage structure of somatic mutations in single cells, combining genotype with cellular phenotype data through machine learning to estimate how far ageing has…
In silico software and AI for small molecule drug discovery
Optibrium is a software company providing integrated computational platforms for small molecule design, optimisation and data analysis across preclinical drug discovery. Its tools support compound property prediction, multi-parameter optimisation, AI-driven data analysis, de novo design, and structure-based modelling,…
AI and quantum-chemical platform for small-molecule drug design
Tres Alchemix is the UK subsidiary of a Japanese biotechnology company developing an AI-driven drug-design platform for small-molecule therapeutics. The platform integrates quantum-level chemical calculations with AI models trained on biochemical and pharmacological datasets to predict the efficacy and safety of novel…
Pre-competitive biologics drug discovery platforms and services for partners
Alloy Therapeutics UK is the Cambridge-based research operation of Alloy Therapeutics, a biotechnology platform company providing pre-competitive drug discovery technologies and services across antibody, TCR, genetic medicine, cell therapy, peptide, and drug delivery modalities. The company offers both discovery…
OrganoMaps AI and multi-omics modelling for drug discovery
AI VIVO is a Cambridge biotechnology company combining machine learning and multi-omics data to model disease biology and drug responses. Its OrganoMaps approach links molecular measurements with tissue and organ-level physiological networks, supporting analysis of therapeutic targets and mechanisms of action. The…
AI-driven neuroimaging analytics for clinical trials
Queen Square Analytics is a UCL spin-out providing advanced neuroimaging data analytics for neurological clinical trials. The company applies machine learning to MRI data for patient stratification, treatment response prediction, and imaging protocol design, with a primary focus on multiple sclerosis and…